secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-TECHNE Corp (TECH)
CIK:        0000842023
Form:       8-K
Filed at:   2026-06-25T12:21:30+00:00
Accession:  0001999371-26-013429
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 7.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck KGaA to acquire Bio-Techne for $73/share in $11.3B deal
-------------------------------------------------------------

- Purchase price $73/share in cash; enterprise value $11.3B (EUR 9.9B); 36% premium to 1-month VWAP.
- Expected to close by late 2026 / early 2027, subject to shareholder and regulatory approvals.
- Annual cost synergies of ~EUR 140M expected fully realized by year 3 post-close.
- Bio-Techne FY2025 net sales >$1.2B; ~3,000 employees; to operate as part of Merck KGaA Life Science.
- Transaction approved by Bio-Techne Board and Merck corporate bodies; debt-funded with investment-grade credit maintained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/842023/000199937126013429/0001999371-26-013429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/842023/000199937126013429/tech-8k_062526.htm
  HTML page:      https://secwatch.observer/filing/0001999371-26-013429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer